According to FutureWise analysis the market for Antihypertensive Drugs to reach US$ 31,106 million in 2022 is projected to expand at a CAGR of 3% over the forecast period of 2023-2031.
Antihypertensive medications fall under several chemical classes and are used to treat, regulate, or prevent hypertension. Antihypertensive medication types differ from one another both structurally and therapeutically. With the rise of hypertension in the general population at 31% in the UK [defined by the National Institute for Health and Care Excellence (NICE) as a measurement of 140/90 mm Hg or higher in clinic, with subsequent ambulatory or home measurement of 135/85 mm Hg or higher], they are crucial in the practise of anaesthesia. Antihypertensive medications are frequently used for unrelated diseases, such as anxiety, thyrotoxicosis, or heart failure. Examples of these include ACEIs for heart failure and -blockers for thyrotoxicosis. Therefore, the medicine and its indication both have an impact on how anaesthetic is administered.
Hypertension, increases the risk of heart ailment and stroke. Hypertension risk factors include obesity, excessive alcohol use, smoking, and a family history. Beta-blockers are routinely used to treat hypertension. High blood pressure, also known as hypertension, is a frequent condition where the blood's long-term pressure against your artery walls is severe enough to potentially harm individual's and lead to coronary heart disease. Drugs for high blood pressure are used to treat patients who have the condition.
FutureWise Market Research has published a report that provides an insightful analysis of antihypertensive drugs market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, the antihypertensive drugs market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.
Major players included in the Antihypertensive Drugs market are:
- Boehringer Ingelheim GmbH.
- Merck KGaA.
- Johnson and Johnson.
- Bayer AG.
- Pfizer, Inc.
- Takeda Pharmaceutical Co.Ltd.
- AstraZeneca plc.
- Daiichi Sankyo Company.
- Sanofi S.A.
- Novartis International AG.
Recent developments by key players in Antihypertensive Drugs Market:
In May 2022-Hanmi Pharmaceutical announced that it will begin selling the popular hypertension medication Amosartan in China under the trade name Meiyaping. It represented the introduction of the first domestic blood pressure combination therapy to the Chinese market.
The increasing prevalence of hypertension worldwide is one of the main drivers of the expansion of the anti-hypertensive medicine market. The rise of hypertension has significantly increased over the past few years due to the major recognised causes of hypertension, which include kidney illnesses, diabetes, obstructive sleep disorders, and other cardiovascular diseases. Additionally, several medications can cause hypertension in people with other illnesses or problems, which is anticipated to expand the market. As of June 2021, cardiovascular diseases (CVDs) were the major cause of mortality globally, accounting for an estimated 17.9 million deaths, according to the World Health Organisation. Moreover, combination medications are now more frequently used in treatment than monotherapy. While combination therapy (the use of various drugs) allows for action on multiple hypertensive processes, monotherapy involves using a single medication to treat hypertension. When the two drugs are combined with different mechanisms of action, the effect is two to five times stronger than monotherapy. When two antihypertensive drugs with different mechanisms of action are combined, coronary events are reduced by 40% and cerebrovascular events by 54%, compared to a higher dose of monotherapy that reduces coronary events by 29% and cerebrovascular events by 40%. A target organ is therefore better protected when combination therapy is used than increasing the monotherapy dose. Therefore, combination therapy is more widely used, effective, and generally well-liked. This has allowed major players to further develop their product and grow their consumer base. However, the general lack of information regarding anti-hypertensive medications is one of the major barriers to market. First of all, the majority of people in developing nations do not get routine medical examinations and are unaware that they have hypertension until they exhibit severe symptoms. The fact that many individuals with hypertension do not follow their prescription schedule and stop taking it after 1-2 weeks until their symptoms emerge poses a significant challenge to the market for anti-hypertensive drugs.